BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26405232)

  • 1. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
    Sabaté M; Windecker S; Iñiguez A; Okkels-Jensen L; Cequier A; Brugaletta S; Hofma SH; Räber L; Christiansen EH; Suttorp M; Pilgrim T; Anne van Es G; Sotomi Y; García-García HM; Onuma Y; Serruys PW
    Eur Heart J; 2016 Jan; 37(3):229-40. PubMed ID: 26405232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
    Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
    EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-endothelialisation after Synergy stent and Absorb bioresorbable vascular scaffold implantation in acute myocardial infarction: COVER-AMI study.
    Lhermusier T; Ohayon P; Boudou N; Bouisset F; Campelo-Parada F; Roncalli J; Elbaz M; Carrié D
    Trials; 2019 Apr; 20(1):210. PubMed ID: 30975219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of MECHANISM of early and late vascular responses following treatment of ST-elevation acute myocardial infarction with two different everolimus-eluting stents: a randomized controlled trial of biodegradable versus durable polymer stents.
    Otake H; Ishida M; Nakano S; Higuchi Y; Hibi K; Kuriyama N; Iwasaki M; Kataoka T; Kubo T; Tsujita K; Ashikaga T; Shinke T; Itoh T; Kimura T; Morino Y;
    Cardiovasc Interv Ther; 2023 Jan; 38(1):75-85. PubMed ID: 35896895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.
    Brugaletta S; Gomez-Lara J; Ortega-Paz L; Jimenez-Diaz V; Jimenez M; Jiménez-Quevedo P; Diletti R; Mainar V; Campo G; Silvestro A; Maristany J; Flores X; Oyarzabal L; De Miguel-Castro A; Iñiguez A; Serra A; Nombela-Franco L; Ielasi A; Tespili M; Lenzen M; Gonzalo N; Bordes P; Tebaldi M; Biscaglia S; Rodriguez-Arias JJ; Al-Shaibani S; Arevalos V; Romaguera R; Gomez-Hospital JA; Serruys PW; Sabaté M
    J Am Coll Cardiol; 2021 Mar; 77(9):1165-1178. PubMed ID: 33663733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data.
    Cassese S; Katagiri Y; Byrne RA; Brugaletta S; Alfonso F; Räber L; Maeng M; Iñiguez A; Kretov E; Onuma Y; Joner M; Sabaté M; Laugwitz KL; Windecker S; Kastrati A; Serruys PW
    EuroIntervention; 2020 Mar; 15(16):1451-1457. PubMed ID: 30719976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
    Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
    Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
    Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
    Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
    Kimura T; Kozuma K; Tanabe K; Nakamura S; Yamane M; Muramatsu T; Saito S; Yajima J; Hagiwara N; Mitsudo K; Popma JJ; Serruys PW; Onuma Y; Ying S; Cao S; Staehr P; Cheong WF; Kusano H; Stone GW;
    Eur Heart J; 2015 Dec; 36(47):3332-42. PubMed ID: 26330419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.
    Byrne RA; Alfonso F; Schneider S; Maeng M; Wiebe J; Kretov E; Bradaric C; Rai H; Cuesta J; Rivero F; Hoppmann P; Schlichtenmaier J; Christiansen EH; Cassese S; Joner M; Schunkert H; Laugwitz KL; Kastrati A
    Eur Heart J; 2019 Jan; 40(2):167-176. PubMed ID: 30520980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study.
    Brugaletta S; Gori T; Tousek P; Gomez-Lara J; Pinar E; Ortega-Paz L; Schulz E; Kocka V; Münzel T; Cequier À; Buono A; Serruys PW; Sabaté M;
    EuroIntervention; 2020 Mar; 15(16):1436-1443. PubMed ID: 31845896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-Year Optical Coherence Tomography in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents.
    Gomez-Lara J; Brugaletta S; Jacobi F; Ortega-Paz L; Ñato M; Roura G; Romaguera R; Ferreiro JL; Teruel L; Gracida M; Martin-Yuste V; Freixa X; Masotti M; Gomez-Hospital JA; Sabate M; Cequier A
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27702766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial.
    Gomez-Lara J; Brugaletta S; Ortega-Paz L; Vandeloo B; Moscarella E; Salas M; Romaguera R; Roura G; Ferreiro JL; Teruel L; Gracida M; Windecker S; Serruys PW; Gomez-Hospital JA; Sabaté M; Cequier A
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1559-1571. PubMed ID: 29805111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
    Pilgrim T; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Losdat S; Eeckhout E; Valgimigli M; Jüni P; Windecker S; Iglesias JF
    JACC Cardiovasc Interv; 2021 Mar; 14(6):639-648. PubMed ID: 33727005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.